foxo4-dri senolytic peptide animal model 2023 2024 Inhibitors Targeting FOXO4-p53 Interactions and Inducing Senescent Cancer Cell-specific Apoptosis Heterogeneity of Cellular Senescence, Senotyping,
Description
Survodutide (BI 456906) is an investigational unimolecular dual agonist developed by Boehringer Ingelheim (licensed from Zealand Pharma) that activates both the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR)
The disulphide bond-containing loop structure may require slightly longer to fully dissolve than linear peptides
* 50 Signifies a bilateral procedure performed on both sides of the body
PubChem Compound Summary for CID 45382195, Thymosin Beta 4
Scopolamine hydrobromide (#S 1875) was purchased from Sigma Chemical (St Louis, MO)
